Our perspectives
in one place
Topic
Selected filters
Clear
News
See allPharmaceutical industry welcomes the launch of Gavi’s new investment round and AVMA
On 20 June in Paris, Gavi, the Vaccine Alliance, the Government of France and the African Union – together with Team Europe partners, co-hosted The Global Forum for Vaccine Sovereignty and Innovation.
Read morePharmaceutical industry response to pandemic preparedness agreements at World Health Assembly
On 1 June, member states represented at the World Health Assembly agreed on amendments to the International Health Regulations (2005), alongside the decision to complete negotiations on a pandemic agreement within a year. The pharmaceutical industry shared its response.
Read moreWHA77 individual statement on the Working Group on Amendments to the International Health Regulations (2005)
On 28 May 2024, IFPMA submitted a statement at the World Health Assembly on Provisional Agenda Item 13.3, Working Group on Amendments to the International Health Regulations (2005). IFPMA acknowledges and appreciates the substantial efforts made by Member States in advancing the text of the Working Group on Amendments to the International Health Regulations (WGIHR)....
Read moreWHA77 constituency statement on INB
On 28 May 2024, IFPMA, GSCF, GMTA, DVCMN, and BIO submitted a statement to the World Health Assembly on Provisional Agenda Item 13.4, Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response.
Read moreWHA77 constituency statement on NCDs and UHC
On 27 May 2024, IFPMA, IGBA, DITTA, GSCF, WHL, and PATH submitted a constituency statement to the World Health Assembly on Provisional Agenda Item 11.2, NCDs and UHC. IFPMA, IGBA, DITTA, GSCF, WHL, and PATH welcome the agenda item on non-communicable diseases (NCDs) and WHO’s continued commitment to this global health challenge. A life-course approach...
Read moreWHA77 individual statement on antimicrobial resistance (AMR)
On 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 11.8, Antimicrobial resistance. We are broadly supportive of the three strategic priorities described previously and welcome the newly included elevated strategic priority on effective governance and financing, which also recognizes the important role of all stakeholders, including the...
Read morePublications
See allThe Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
The development and manufacture of vaccines to protect global health (IFPMA & DCVMN)
IFPMA has partnered with DCVMN to share our industry’s expertise in vaccine development and manufacturing. This presentation illustrates the key stages and timeline to bring vaccines to the market.
Read more
From resistance to resilience: what could the future antibiotic pipeline look like?
In a new report, IFPMA reviews the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest concern, and presents modelling data on the future of the pipeline.
Read more
Expert insights
See all
Now is the time for sustainable financing for NCDs and mental health
Read more
Operationalising the African regulatory ecosystem for the benefit of all patients
Read more
Adult immunisation programmes boost public health and economic prosperity
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more